James M. Grichnik
Expertise in
11
conditions

Dr. James M. Grichnik

Dermatology
Univ. Medical Service Association Inc.
13330 Usf Laurel Dr, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
11
conditions
Univ. Medical Service Association Inc.
13330 Usf Laurel Dr, 
Tampa, FL 

Overview

James Grichnik is a Dermatologist practicing medicine in Tampa, Florida.

Dr. Grichnik is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Melanoma, Familial Atypical Multiple Mole Melanoma Syndrome, Seborrheic Keratosis, and Sunburn.

He is actively involved in clinical research, co-authoring 61 peer reviewed articles and participating in 12 clinical trials. Dr. Grichnik is currently accepting new patients.

Specialties

Dermatology

Licenses

Dermatology in NC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Univ. Medical Service Association Inc.
13330 Usf Laurel Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Other
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
View 9 Less Clinical Trials

61 Total Publications

Antimicrobial Peptides of the Skin: Roles in Skin Cancer and Clinical Applications.
Antimicrobial Peptides of the Skin: Roles in Skin Cancer and Clinical Applications.
Journal: Experimental dermatology
Published: April 12, 2026
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required
Before you request

H Lee Moffitt Cancer Center And Research

10920 McKinley Dr, 
Tampa, FL 
 (1.4 miles away)
813-745-8414
Languages Spoken:
English, German, Spanish
See accepted insurances
Accepting New Patients

Lucia Seminario-Vidal is a Dermatologist practicing medicine in Tampa, Florida. Dr. Seminario-Vidal is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, T-Cell Lymphoma, Erythema Multiforme, and Bone Marrow Aspiration. Dr. Seminario-Vidal is currently accepting new patients.

Expertise in
28
conditions
Dr. Seth B. Forman
Dermatology
Expertise in
28
conditions
Dr. Seth B. Forman
Dermatology
Referral may be required

Phdermatology

15416 N Florida Ave, 
Tampa, FL 
 (3.1 miles away)
813-960-2400
Languages Spoken:
English
See accepted insurances

Seth Forman is a Dermatologist practicing medicine in Tampa, Florida. Dr. Forman is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Atopic Dermatitis, Hidradenitis Suppurativa, Plaque Psoriasis, and Psoriasis. Dr. Forman is board certified in American Board Of Dermatology.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

Moffitt McKinley Campus

10920 McKinley Dr, 
Tampa, FL 
 (1.4 miles away)
888-663-3488
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Kenneth Tsai is a Dermatologist practicing medicine in Tampa, Florida. Dr. Tsai is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Squamous Cell Skin Carcinoma, and Actinic Keratosis. Dr. Tsai is currently accepting new patients.

Frequently Asked Questions about Dr. James M. Grichnik

How do I make an appointment with Dr. James M. Grichnik?

You can book an appointment with Dr. James M. Grichnik by calling their office at 813-974-4270. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James M. Grichnik a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James M. Grichnik is classified as an Distinguished expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James M. Grichnik specialize in?

While Dr. James M. Grichnik is a Dermatology, they have specific expertise in Melanoma, Familial Atypical Multiple Mole Melanoma Syndrome, and Seborrheic Keratosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. James M. Grichnik participate in research or clinical trials?

Yes. Dr. James M. Grichnik has published 61 articles and abstracts on conditions like Melanoma. You can view a list of Dr. James M. Grichnik's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James M. Grichnik accept my insurance?

Dr. James M. Grichnik accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-974-4270 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grichnik's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile